The effect of somatostatin and its analogs in the prevention of pancreatic fistula after elective pancreatic surgery

European Surgery - Acta Chirurgica Austriaca

Volumn 44, Issue 2, 2012, Pages 99-108

  Cecka F ^a   Jon, B ^a   Subrt Z ^b   Ferko, A ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Octreotide; Pancreatic fistula; Pancreatic surgery; Postoperative complications; Somatostatin

Indexed keywords

OCTREOTIDE; PLACEBO; SOMATOSTATIN DERIVATIVE; VAPREOTIDE;

CANCER RADIOTHERAPY; CHRONIC PANCREATITIS; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; ELECTIVE SURGERY; HUMAN; META ANALYSIS (TOPIC); MORBIDITY; MULTICENTER STUDY (TOPIC); PANCREAS CARCINOMA; PANCREAS FISTULA; PANCREAS SURGERY; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW;

EID: 84865506222     PISSN: 16828631     EISSN: 16824016     Source Type: Journal    
DOI: 10.1007/s10353-011-0612-z     Document Type: Review

References (66)

1. Kausch W. Das Karcinom der Papilla duodeni und seine radikale Entfernung. Beitr Klin Chir 1912;78:439-51.
2. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg 1935;102:763-79.
3. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987;206:358-65.
4. Bassi C, Falconi M, Salvia R, et al. Management of complications after pancreaticoduodenectomy in a high-volume centre: results on 150 consecutive patients. Dig Surg 2001;18:453-7.
5. Bottger TC, Junginger T. Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections. World J Surg 1999;23:164-71.
6. Gouma DJ, van Geenen RC, van Gulik TM, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000; 232:786-95.
7. Buchler MW, Wagner M, Schmied BM, et al. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg 2003;138:1310-4.
8. DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg 2006;244:931-7.
9. Vin Y, Sima CS, Getrajdman GI, et al. Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg 2008;207:490-8.
10. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199-210.
11. Balcom JH, Rattner DW, Warshaw AL, et al. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001;136:391-8.
12. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10-5.
13. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990;211:447-58.
14. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-57.
15. Kleespies A, Albertsmeier M, Obeidat F, et al. The challenge of pancreatic anastomosis. Langenbecks Arch Surg 2008;393: 459-71.
16. Holbrook RF, Hargrave K, Traverso LW. A prospective cost analysis of pancreatoduodenectomy. Am J Surg 1996;171: 508-11.
17. Knaebel HP, Diener MK, Wente MN, et al. Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. Br J Surg 2005;92:539-46.
18. Poon RT, Fan ST, Lo CM, et al. External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. Ann Surg 2007;246:425-33.
19. Wente MN, Shrikhande SV, Muller MW, et al. Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis. Am J Surg 2007;193:171-83.
20. Winter JM, Cameron JL, Campbell KA, et al. Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg 2006;10:1280-90.
21. Langrehr JM, Bahra M, Jacob D, et al. Prospective randomized comparison between a new mattress technique and Cattell (duct-to-mucosa) pancreaticojejunostomy for pancreatic resection. World J Surg 2005;29:1111-9.
22. Peng SY, Mou YP, Liu YB, et al. Binding pancreaticojejunostomy: 150 consecutive cases without leakage. J Gastrointest Surg 2003; 7:898-900.
23. Sutton CD, Garcea G, White SA, et al. Isolated Roux-loop pancreaticojejunostomy: a series of 61 patients with zero postoperative pancreaticoenteric leaks. J Gastrointest Surg 2004;8:701-5.
24. Watanabe M, Usui S, Kajiwara H, et al. Current pancreatogastrointestinal anastomotic methods: results of a Japanese survey of 3109 patients. J Hepatobiliary Pancreat Surg 2004;11:25-33.
25. Klempa I, Schwedes U, Usadel KH. Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin. Chirurg 1979;50:427-31.
26. Raptis S, Schlegel W, Lehmann E, et al. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones. Metabolism 1978;27:1321-8.
27. Sheppard M, Shapiro B, Pimstone B, et al. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 1979;48:50-3.
28. Heintges T, Luthen R, Niederau C. Inhibition of exocrine pancreatic secretion by somatostatin and its analogues. Digestion 1994;55(Suppl. 1):1-9.
29. Klempa I, Baca I, Menzel J, et al. Effect of somatostatin on basal and stimulated exocrine pancreatic secretion after partial duodenopancreatectomy. A clinical experimental study. Chirurg 1991;62:293-9.
30. Gyr KE, Meier R. Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. Digestion 1993;54(Suppl. 1):14-9.
31. Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med 1996;334:246-54.
32. Williams ST, Woltering EA, O'Dorisio TM, et al. Effect of octreotide acetate on pancreatic exocrine function. Am J Surg 1989; 157:459-62.
33. Falconi M, Contro C, Ballabio M, et al. Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: preliminary study. Dig Liver Dis 2002;34:127-32.
34. Lamrani A, Vidon N, Sogni P, et al. Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans. Br J Clin Pharmacol 1997; 43:65-70.
35. Ritz MA, Drewe J, Ziel A, et al. The effects of vapreotide, a somatostatin analogue, on gastric acidity, gallbladder emptying and hormone release after 1 week of continuous subcutaneous infusion in normal subjects. Br J Clin Pharmacol 1999;47: 195-201.
36. Buchler M, Friess H, Klempa I, et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg 1992;163:125-30.
37. Pederzoli P, Bassi C, Falconi M, et al. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian Study Group. Br J Surg 1994;81:265-9.
38. Friess H, Beger HG, Sulkowski U, et al. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg 1995;82:1270-3.
39. Montorsi M, Zago M, Mosca F, et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery 1995;117:26-31.
40. Lowy AM, Lee JE, Pisters PW, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 1997;226:632-41.
41. Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000;232:419-29.
42. Gouillat C, Chipponi J, Baulieux J, et al. Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy. Br J Surg 2001;88:1456-62.
43. Shan YS, Sy ED, Lin PW. Role of somatostatin in the prevention of pancreatic stump-related morbidity following elective pancreaticoduodenectomy in high-risk patients and elimination of surgeon-related factors: prospective, randomized, controlled trial. World J Surg 2003;27:709-14.
44. SarrMG. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg 2003;196:556-64.
45. Suc B, Msika S, PiccininiM, et al. Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial. Arch Surg 2004;139:288-94.
46. Hesse UJ, De Decker C, Houtmeyers P, et al. Prospectively randomized trial using perioperative low dose octreotide to prevent organ related and general complications following pancreatic surgery and pancreatico-jejunostomy. Acta Chir Belg 2005;105:383-7.
47. Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl JMed 2003;349: 2117-27.
48. Eppsteiner RW, Csikesz NG, McPhee JT, et al. Surgeon volume impacts hospital mortality for pancreatic resection. Ann Surg 2009;249:635-40.
49. Nathan H, Cameron JL, Choti MA, et al. The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship. J Am Coll Surg 2009;208:528-38.
50. Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998;228:429-38.
51. Li-Ling J, Irving M. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg 2001;88:190-9.
52. Friess H, Bordihn K, Ebert M, et al. Inhibition of pancreatic secretion under long-term octreotide treatment in humans. Digestion 1994;55(Suppl. 1):10-5.
53. Londong W, Angerer M, Kutz K, et al. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 1989; 96:713-22.
54. Gouillat C, Gigot JF. Pancreatic surgical complications - the case for prophylaxis. Gut 2001;49(Suppl. 4):32-9.
55. Closset J, Journe S, Mboti F, et al. Randomized controlled trial comparing somatostatin with octreotide in the prevention of complications after pancreatectomy. Hepatogastroenterology 2008;55:1818-23.
56. Rosenberg L, MacNeil P, Turcotte L. Economic evaluation of the use of octreotide for prevention of complications following pancreatic resection. J Gastrointest Surg 1999;3:225-32.
57. Poon RT, Lo SH, Fong D, et al. Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. Am J Surg 2002; 183:42-52.
58. Connor S, Alexakis N, Garden OJ, et al. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg 2005;92: 1059-67.
59. Alghamdi AA, Jawas AM, Hart RS. Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis. Can J Surg 2007;50: 459-66.
60. Zeng Q, Zhang Q, Han S, et al. Efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. Pancreas 2008;36:18-25.
61. Koti RS, Gurusamy KS, Fusai G, et al. Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. HPB (Oxford) 2010;12:155-65.
62. Lai E, Lau S, Lau WY. Measures to prevent pancreatic fistula after pancreatoduodenectomy. A comprehensive review. Arch Surg 2009;144:1074-80.
63. Bassi C, Butturini G, Molinari E, et al. Pancreatic fistula rate after pancreatic resection. The importance of definitions. Dig Surg 2004;21:54-9.
64. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8-13.
65. Ho CK, Kleeff J, Friess H, et al. Complications of pancreatic surgery. HPB (Oxford) 2005;7:99-108.
66. Stojadinovic A, Brooks A, Hoos A, et al. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg 2003;196:954-64.